US 12,291,563 B2
Metabolically optimized cell culture
Shawn Lawrence, Valley Cottage, NY (US); Michelle Lafond, Pleasantville, NY (US); Ann Kim, White Plains, NY (US); Amy S. Johnson, Briarcliff Manor, NY (US); Brandon Veres, White Plains, NY (US); Mark Czeterko, Stamford, CT (US); and Kristen Whalen, Brookhaven, GA (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed on Jun. 17, 2022, as Appl. No. 17/843,121.
Application 17/843,121 is a continuation of application No. 15/130,611, filed on Apr. 15, 2016, granted, now 11,390,663.
Application 15/130,611 is a continuation in part of application No. 15/028,521, abandoned, previously published as PCT/US2014/059993, filed on Oct. 10, 2014.
Claims priority of provisional application 61/889,815, filed on Oct. 11, 2013.
Prior Publication US 2022/0315644 A1, Oct. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/00 (2006.01); C07H 21/04 (2006.01); C12N 5/00 (2006.01); C12P 21/02 (2006.01); C12Q 3/00 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/00 (2013.01) [C12P 21/02 (2013.01); C12Q 3/00 (2013.01); C07H 21/04 (2013.01); C07K 2317/14 (2013.01); C12N 5/0006 (2013.01); C12N 15/63 (2013.01); C12N 2510/00 (2013.01)] 15 Claims
 
1. A method for culturing cells comprising:
(a) culturing cells in a first seed train culture to a viable cell concentration of greater than 3.0×106 cells/mL, whereby a metabolic shift to lactate consumption has occurred in the first seed train culture;
(b) transferring an amount of cells from the first seed train culture to a second seed train culture in another culture vessel;
(c) culturing the cells in the second seed train culture; and
(d) transferring an amount of cells from the second seed train culture to a production culture after the cells in the second seed train culture have reached a predetermined viable cell concentration greater than 3.0×106 cells/mL.